New solution offers real-time data exchange and inventory control, ensuring sample integrity.
Slope and LabConnect have unveiled their new bidirectional API integration. The solution builds on the existing collaboration between the organizations, offering a more comprehensive and seamless connection between Slope's Biospecimen360 platform and LabConnect's Laboratory Information Management System (LIMS).1
Marking the first integration of its kind in the clinical trial industry, it enables real-time, bidirectional data exchange. This includes all sample and subject metadata, as well as comprehensive kit and bulk supply inventory control from lab to site, at the site, and data-driven kit reordering back to LabConnect.
Key features of the new integration include:
"This enhanced integration marks a significant advancement in biospecimen management," Rust Felix, CEO of Slope, said in a press release. "As part of our vendor-agnostic approach, Slope is committed to building an integrated lab ecosystem, with LabConnect as a key partner. This transformation sets a new standard for real-time data exchange in clinical trials, revolutionizing how the industry manages sample data and inventory."
In the same press release, Wes Wheeler, CEO of LabConnect, added, "The integrity of assay results begins with the integrity of the sample. Our integration with Slope ensures that every step of the biospecimen lifecycle is monitored, controlled, and documented with unparalleled accuracy. This level of data integrity has never before been achieved in our industry."
This new integration underscores Slope’s focus on standardizing data transfer, as well as streamlining traditional processes with new technology. From a Q&A with Applied Clinical Trials in April, Felix emphasized the industry’s challenges with ensuring data quality.
“One of the primary challenges the industry must confront is the issue of data quality and lack of standardization, especially in the context of biospecimen lifecycle management. Currently, the process is exceedingly manual, defined by paper-centric processes, complex sample management schemes, and an expanding volume of sample collections. The escalation in study complexity has precipitated a staggering increase in the number of procedures, endpoints, and data points collected, as evidenced by an analysis of nearly 10,000 clinical trial protocols,” he said.
1. Slope and LabConnect Unveil Groundbreaking Bidirectional API Integration for Clinical Trials. News release. Slope. November 25, 2024. Accessed November 27, 2024. https://www.prnewswire.com/news-releases/slope-and-labconnect-unveil-groundbreaking-bidirectional-api-integration-for-clinical-trials-302315037.html
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Phase III MOVe-NOW Trial to Evaluate New Lagevrio Formulation Targeting High-Risk COVID-19 Patients
December 6th 2024Merck and Ridgeback Biotherapeutics have launched the Phase III MOVe-NOW trial to evaluate a new, streamlined formulation of Lagevrio (molnupiravir) for treating non-hospitalized COVID-19 patients at high risk of severe disease progression who are unable to use other antiviral therapies.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Phase II Piranga Trial Shows Promise of Xalnesiran Combination for Hepatitis B Treatment
December 5th 2024Phase II Piranga trial found that the combination of xalnesiran and an immunomodulator effectively reduced hepatitis B surface antigen (HBsAg) levels, but highlighted challenges in response durability and efficacy in patients with high HBsAg levels.